The late-breaking oral session at the European Hematology Association (EHA) 2024 Congress featured new data from abstracts submitted after the deadline, including both interventional and foundational ...
Rhythm Pharmaceuticals announced three late-breaking abstracts accepted for presentation at ENDO 2025, highlighting new research on acquired hypothalamic obesity treatments. Rhythm Pharmaceuticals, a ...
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-breaking abstract was accepted for an oral ...
Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) Poster to highlight long-term therapeutic benefits of THIO sequenced with ...
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients ...
Abstract Title: A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks Click to enlarge “We are pleased that the ACR has recognized the importance of this ...
Jaguar has also completed enrollment of pediatric MVID patients in an ongoing randomized clinical trial with plans for an NDA filing in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2026 / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results